BioXcel Therapeutics, Inc. (BTAI)
NASDAQ · Healthcare
BioXcel Therapeutics, Inc. Total Liabilities 2022–2025
BioXcel Therapeutics, Inc. annual/quarterly total liabilities history from 2022 to 2025. Total liabilities is the combined debt and financial obligations a company owes to creditors.
- BioXcel Therapeutics, Inc. total liabilities for the quarter ending December 31, 2025 were 140.4M, a 6.80% increase year-over-year.
- BioXcel Therapeutics, Inc. total liabilities for 2025 were 140.4M, a 6.80% increase from 2024.
- BioXcel Therapeutics, Inc. total liabilities for 2024 were 131.4M, a 0.94% increase from 2023.
- BioXcel Therapeutics, Inc. total liabilities for 2023 were 130.2M, a 0.88% increase from 2022.
- BioXcel Therapeutics, Inc. total liabilities for 2022 were 129.1M.
Total Liabilities
QUARTERLY · $B
YOY QUARTERLY GROWTH · %
| BioXcel Therapeutics, Inc. Annual Total Liabilities (Millions of US $) | |
|---|---|
| 2025 | $140 |
| 2024 | $131 |
| 2023 | $130 |
| 2022 | $129 |
| BioXcel Therapeutics, Inc. Quarterly Total Liabilities (Millions of US $) | |
|---|---|
| 2025-12-31 | $140 |
| 2024-12-31 | $131 |
| 2023-12-31 | $130 |
| 2022-12-31 | $129 |
BioXcel Therapeutics, Inc. Total Liabilities — FAQ
BioXcel Therapeutics, Inc. (BTAI) total liabilities over the last 4 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BTAI's total liabilities history?
The chart and table above show BioXcel Therapeutics, Inc.'s total liabilities by year and by quarter, including the growth rate.